##analysisDate=2017-11-06-11-14-29000
##analyzedBy=RingStudy Site D
##exportDate=2017-11-06-13-50-39000
##analysisName=Site D-Sample 8 phase I
##workflowName=Oncomine Focus w2.1 - DNA and Fusions - Single Sample
##sampleNames=sample 8_v1:sample 8_RNA_v1
##reference=hg19
##variantGroup=DEFAULT
##filterChain=Site D_NoRef
##searchText=
##chromosome=All
##totalVariantCount=827
##filterInCount=13
##filteredOutCount=814
##hiddenVariantCount=0
Locus	Genotype	Ref	Type	No Call Reason	Genes	Location	Length	Oncomine Variant Class	Oncomine Gene Class	Copy Number	CytoBand	Info	Variant ID	Variant Name	% Frequency	Amino Acid Change	Read Counts	Coverage	Allele Ratio	CNV Confidence	Detection	3'/5' Imbalance	COSMIC/NCBI	Read Counts Per Million	Strand	Exon	Transcript	Coding	Variant Effect	PhyloP	SIFT	Grantham	PolyPhen	PFAM	dbSNP	DGV	MAF	EMAF	AMAF	GMAF	UCSC Common SNPs	Gene Ontology	DrugBank	ClinVar	p-value	Phred QUAL Score	Allele Coverage	CNV Precision	Ref+/Ref-/Var+/Var-	Homopolymer Length	Tiles
chr1:65310489	T/C	T	SNV		JAK1	exonic	1								51.12	p.(=)		1119	T=0.4888, C=0.5112		Present				-	16	NM_002227.2	c.2199A>G	synonymous	-4.13				Protein kinase domain,Protein tyrosine kinase	rs2230588		0.352 (ref)	0.2323	0.418	0.3492	YES	ATP binding,cytokine-mediated signaling pathway,cytoplasm,cytoskeleton,cytosol,endomembrane system,growth hormone receptor binding,interferon-gamma-mediated signaling pathway,intracellular protein kinase cascade,intracellular signal transduction,membrane,non-membrane spanning protein tyrosine kinase activity,nucleotide binding,nucleus,protein binding,protein phosphorylation,protein tyrosine kinase activity,regulation of interferon-gamma-mediated signaling pathway,regulation of type I interferon-mediated signaling pathway,response to antibiotic,type I interferon-mediated signaling pathway	2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZH-IMIDAZ4,5-FISOQUINOLIN-7-ONE,3-{(3R,4R)-4-methyl-3-methyl(7H-pyrrolo2,3-dpyrimidin-4-yl)aminopiperidin-1-yl}-3-oxopropanenitrile		0.00001	4479.98	T=547, C=572		T=321/226, C=328/244	1	
chr2:29416366	C/C	G	SNV		ALK	exonic	1								100.00	p.Asp1529Glu		1290	G=0.0, C=1.0		Present				-	29	NM_004304.4	c.4587C>G	missense	-1.46	1.0	45.0	0.0	MAM domain,Protein kinase domain,Protein tyrosine kinase	rs1881421		0.435 (ref)	0.3438	0.3915	0.4335	YES	ATP binding,NF-kappaB-inducing kinase activity,activation of MAPK activity,cell proliferation,integral to plasma membrane,neuron development,nucleotide binding,phosphorylation,plasma membrane,positive regulation of NF-kappaB transcription factor activity,protein autophosphorylation,receptor activity,regulation of apoptotic process,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	17318.1	G=0, C=1290		G=0/0, C=631/659	1	
chr2:29416572	C/C	T	SNV		ALK	exonic	1								100.00	p.Ile1461Val		2000	T=0.0, C=1.0		Present				-	29	NM_004304.4	c.4381A>G	missense	-0.25	1.0	29.0	0.0	MAM domain,Protein kinase domain,Protein tyrosine kinase	rs1670283		0.007 (ref)	3.0E-4	0.0279	0.0097		ATP binding,NF-kappaB-inducing kinase activity,activation of MAPK activity,cell proliferation,integral to plasma membrane,neuron development,nucleotide binding,phosphorylation,plasma membrane,positive regulation of NF-kappaB transcription factor activity,protein autophosphorylation,receptor activity,regulation of apoptotic process,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	26971.9	T=0, C=2000		T=0/0, C=940/1060	1	
chr2:29443617	C/G	C	SNV		ALK	exonic	1								43.35	p.(=)		1421	C=0.5665, G=0.4335		Present				-	23	NM_004304.4	c.3600G>C	synonymous	-3.3				MAM domain,Protein kinase domain,Protein tyrosine kinase	rs56247462		0.012	2.0E-4	0.0011	5.0E-4		ATP binding,NF-kappaB-inducing kinase activity,activation of MAPK activity,cell proliferation,integral to plasma membrane,neuron development,nucleotide binding,phosphorylation,plasma membrane,positive regulation of NF-kappaB transcription factor activity,protein autophosphorylation,receptor activity,regulation of apoptotic process,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	4273.34	C=805, G=616		C=465/340, G=360/256	6	
chr2:29445458	T/T	G	SNV		ALK	exonic	1								99.10	p.(=)		1110	G=0.009, T=0.991		Present				-	21	NM_004304.4	c.3375C>A	synonymous	-1.83				MAM domain,Protein kinase domain,Protein tyrosine kinase	rs3795850		0.395 (ref)	0.2058	0.2519	0.2214	YES	ATP binding,NF-kappaB-inducing kinase activity,activation of MAPK activity,cell proliferation,integral to plasma membrane,neuron development,nucleotide binding,phosphorylation,plasma membrane,positive regulation of NF-kappaB transcription factor activity,protein autophosphorylation,receptor activity,regulation of apoptotic process,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	14586.5	G=10, T=1100		G=5/5, T=546/554	1	
chr3:178927980	T/C	T	SNV		PIK3CA	exonic	1	Hotspot	Gain-of-function			HS	COSM757		32.75	p.Cys420Arg		2000	T=0.6725, C=0.3275		Present				+	8	NM_006218.2	c.1258T>C	missense	2.11	0.06	180.0	0.997	PI3-kinase family,Phosphatidylinositol 3- and 4-kinase,Phosphoinositide 3-kinase C2,Phosphoinositide 3-kinase family	rs121913272							1-phosphatidylinositol-3-kinase activity,ATP binding,T cell costimulation,T cell receptor signaling pathway,angiogenesis,anti-apoptosis,blood coagulation,cytosol,epidermal growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway,glucose metabolic process,hypomethylation of CpG island,insulin receptor signaling pathway,insulin receptor substrate binding,kinase activity,lamellipodium,leukocyte migration,nerve growth factor receptor signaling pathway,nucleotide binding,phosphatidylinositol 3-kinase complex,phosphatidylinositol phosphorylation,phosphatidylinositol-4,5-bisphosphate 3-kinase activity,phosphatidylinositol-mediated signaling,phosphotransferase activity, alcohol group as acceptor,platelet activation,positive regulation of peptidyl-serine phosphorylation,protein binding,protein kinase B signaling cascade,protein kinase activator activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of multicellular organism growth,signal transduction	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-(METHYLOXY)METHYL-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO4,3,2-DEINDENO4,5-H2BENZOPYRAN-11-YL ACETATE	other	0.00001	4296.88	T=1345, C=655		T=597/748, C=295/360	1	
chr4:1807894	A/A	G	SNV		FGFR3	exonic	1								100.00	p.(=)		1037	G=0.0, A=1.0		Present				+	14	NM_000142.4	c.1953G>A	synonymous	0.05				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs7688609		0.042 (ref)	8.0E-4	0.131	0.0449	YES	ATP binding,JAK-STAT cascade,MAPKKK cascade,bone maturation,bone morphogenesis,chondrocyte differentiation,chondrocyte proliferation,cytoplasmic membrane-bounded vesicle,endochondral bone growth,endochondral ossification,endoplasmic reticulum,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,focal adhesion,insulin receptor signaling pathway,integral to plasma membrane,negative regulation of developmental growth,nucleotide binding,peptidyl-tyrosine phosphorylation,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of MAPKKK cascade,positive regulation of cell proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phospholipase activity,positive regulation of tyrosine phosphorylation of Stat1 protein,positive regulation of tyrosine phosphorylation of Stat3 protein,protein autophosphorylation,protein binding,protein tyrosine kinase activity,receptor activity,regulation of apoptotic process,skeletal system development	Palifermin,Pazopanib		0.00001	13953.0	G=0, A=1037		G=0/0, A=603/434	1	
chr4:55141055	G/G	A	SNV		PDGFRA	exonic	1								100.00	p.(=)		750	A=0.0, G=1.0		Present				+	12	NM_006206.4	c.1701A>G	synonymous	-5.31				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs121913270,rs121913271,rs1873778		0.037 (ref)	0.0015	0.1185	0.0411	YES	ATP binding,Leydig cell differentiation,adrenal gland development,cardiac myofibril assembly,cell activation,cell chemotaxis,cellular response to amino acid stimulus,cytoplasm,elevation of cytosolic calcium ion concentration,embryonic cranial skeleton morphogenesis,embryonic digestive tract morphogenesis,embryonic skeletal system morphogenesis,estrogen metabolic process,extracellular matrix organization,face morphogenesis,female gonad development,gliogenesis,growth factor binding,in utero embryonic development,inner ear development,integral to plasma membrane,intrinsic to plasma membrane,lung development,luteinization,male genitalia development,metanephric glomerular capillary formation,multicellular organismal development,negative regulation of platelet activation,nucleotide binding,nucleus,odontogenesis of dentin-containing tooth,palate development,peptidyl-tyrosine phosphorylation,phosphatidylinositol 3-kinase binding,phosphatidylinositol-mediated signaling,plasma membrane,platelet aggregation,platelet-derived growth factor alpha-receptor activity,platelet-derived growth factor binding,platelet-derived growth factor receptor binding,platelet-derived growth factor receptor signaling pathway,platelet-derived growth factor receptor-alpha signaling pathway,positive regulation of DNA replication,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of fibroblast proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of phospholipase C activity,protein autophosphorylation,protein homodimerization activity,protein tyrosine kinase activity,receptor activity,regulation of actin cytoskeleton reorganization,regulation of chemotaxis,regulation of mesenchymal stem cell differentiation,response to cytokine stimulus,response to estradiol stimulus,response to hormone stimulus,response to hyperoxia,response to inorganic substance,retina vasculature development in camera-type eye,signal transduction involved in regulation of gene expression,transmembrane receptor protein tyrosine kinase activity,vascular endothelial growth factor receptor signaling pathway,vascular endothelial growth factor-activated receptor activity,wound healing	Becaplermin,Imatinib,Pazopanib,Sunitinib		0.00001	9988.64	A=0, G=750		A=0/0, G=458/292	1	
chr5:176517797	T/T	C	SNV		FGFR4	exonic	1								100.00	p.Pro136Leu		580	C=0.0, T=1.0		Present				+	4	NM_213647.1	c.407C>T	missense	1.12	0.3	98.0	0.0	Immunoglobulin I-set domain,Immunoglobulin V-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs376618		0.185 (ref)	0.248	0.3393	0.2789	YES	ATP binding,alveolar secondary septum development,cell migration,cell-cell junction,cytoplasm,endoplasmic reticulum,endosome,extracellular region,fibroblast growth factor 1 binding,fibroblast growth factor 2 binding,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,glucose homeostasis,heparin binding,insulin receptor signaling pathway,integral to plasma membrane,lung development,nucleolus,nucleotide binding,nucleus,organ induction,peptidyl-tyrosine phosphorylation,phosphate ion homeostasis,plasma membrane,positive regulation of DNA biosynthetic process,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell proliferation,positive regulation of metalloenzyme activity,positive regulation of proteolysis,protein autophosphorylation,protein tyrosine kinase activity,receptor activity,regulation of bile acid biosynthetic process,regulation of cholesterol homeostasis,regulation of extracellular matrix disassembly,regulation of lipid metabolic process	Palifermin		0.00001	7747.05	C=0, T=580		C=0/0, T=338/242	4	
chr6:117711009, chr6:117632280			ASSAYS_5P_3P		ROS1								ROS1.5p_NM_002944.2.e11e12,ROS1.3p_NM_002944.2.e38e39				15548,25514				Absent, LOW_5P_3P_IMBALANCE_SCORE	1.8153		3.3180e-07,5.4448e-07																						0.0					
chr7:55242467	AATTAAGAGAAGCAACATCTCC/AATCTCC	AATTAAGAGAAGCAACATCTCC	INDEL		EGFR	exonic	15	Hotspot	Gain-of-function			HS	COSM144207;COSM28623;COSM53205;COSM18421;COSM12369;COSM12386;COSM133193;COSM52935;COSM12416;COSM6220;COSM12384;COSM18426;COSM674057;COSM18427;COSM255211;COSM51524		CACCAACATCTCC=0.00, TCCCTACATCTCC=0.00, TGGCATCTCC=0.00, TTCCATCTCC=0.00, AATCTCC=33.29, TATCTCC=0.00, TCTCTCC=0.00, TTCCTTCTCC=0.00, TTGCTTCTCC=0.00, ATCC=0.00, TTCC=0.00, TCCC=0.00, TGCC=0.00, TCTC=0.00, A=0.00, TTCA=0.00	p.Leu747_Thr751del		1496	AATTAAGAGAAGCAACATCTCC=0.6671, CACCAACATCTCC=0.0, TCCCTACATCTCC=0.0, TGGCATCTCC=0.0, TTCCATCTCC=0.0, AATCTCC=0.3329, TATCTCC=0.0, TCTCTCC=0.0, TTCCTTCTCC=0.0, TTGCTTCTCC=0.0, ATCC=0.0, TTCC=0.0, TCCC=0.0, TGCC=0.0, TCTC=0.0, A=0.0, TTCA=0.0		Present				+	19	NM_005228.3	c.2240_2254delTAAGAGAAGCAACAT	nonframeshiftDeletion	0.98,-0.2,0.39,2.07,-1.46,-0.61,2.56,0.07,2.56,2.07,0.39,2.56,2.56,-0.63,2.07,2.56,-2.87,2.07,1.3,0.86,2.56,2.56				Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain	rs121913229,rs121913231,rs121913421,rs121913422,rs121913423,rs121913424,rs121913425,rs121913426,rs121913435,rs121913436,rs121913437,rs121913438,rs121913439,rs121913440,rs121913441,rs121913442,rs121913463,rs121913464							AP-2 adaptor complex,ATP binding,Golgi apparatus,Golgi membrane,MAP/ERK kinase kinase activity,Shc-EGFR complex,actin filament binding,activation of phospholipase A2 activity by calcium-mediated signaling,activation of phospholipase C activity,axon guidance,basolateral plasma membrane,cell morphogenesis,cell proliferation,cell surface receptor linked signaling pathway,cell-cell adhesion,cerebral cortex cell migration,cytoplasm,digestive tract morphogenesis,double-stranded DNA binding,embryonic placenta development,endocytic vesicle,endoplasmic reticulum,endoplasmic reticulum membrane,endosome,endosome membrane,enzyme binding,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,extracellular region,extracellular space,hair follicle development,identical protein binding,integral to membrane,intracellular,membrane,membrane raft,morphogenesis of an epithelial fold,multicellular organismal development,negative regulation of apoptotic process,negative regulation of epidermal growth factor receptor signaling pathway,negative regulation of protein catabolic process,nitric-oxide synthase regulator activity,nuclear membrane,nucleotide binding,nucleus,ossification,perinuclear region of cytoplasm,plasma membrane,positive regulation of DNA repair,positive regulation of DNA replication,positive regulation of MAP kinase activity,positive regulation of catenin import into nucleus,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of cyclin-dependent protein kinase activity involved in G1/S,positive regulation of epithelial cell proliferation,positive regulation of fibroblast proliferation,positive regulation of nitric oxide biosynthetic process,positive regulation of phosphorylation,positive regulation of protein kinase B signaling cascade,protein autophosphorylation,protein binding,protein heterodimerization activity,protein insertion into membrane,protein phosphatase binding,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of nitric-oxide synthase activity,regulation of peptidyl-tyrosine phosphorylation,response to UV-A,response to stress,salivary gland morphogenesis,signal transducer activity,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane signaling receptor activity	Cetuximab,Erlotinib,Flavopiridol,Gefitinib,Lapatinib,Lidocaine,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,Panitumumab,S-{3-(4-ANILINOQUINAZOLIN-6-YL)AMINO-3-OXOPROPYL}-L-CYSTEINE,Trastuzumab,ZD-6474		0.00001	3290.63	AATTAAGAGAAGCAACATCTCC=998, CACCAACATCTCC=0, TCCCTACATCTCC=0, TGGCATCTCC=0, TTCCATCTCC=0, AATCTCC=498, TATCTCC=0, TCTCTCC=0, TTCCTTCTCC=0, TTGCTTCTCC=0, ATCC=0, TTCC=0, TCCC=0, TGCC=0, TCTC=0, A=0, TTCA=0		AATTAAGAGAAGCAACATCTCC=604/394, CACCAACATCTCC=0/0, TCCCTACATCTCC=0/0, TGGCATCTCC=0/0, TTCCATCTCC=0/0, AATCTCC=293/205, TATCTCC=0/0, TCTCTCC=0/0, TTCCTTCTCC=0/0, TTGCTTCTCC=0/0, ATCC=0/0, TTCC=0/0, TCCC=0/0, TGCC=0/0, TCTC=0/0, A=0/0, TTCA=0/0	2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2	
chr10:43606730, chr10:43622086			ASSAYS_5P_3P		RET								RET.5p_NM_020975.4.e6e7,RET.3p_NM_020975.4.e18e19				99,200				Absent, LOW_5P_3P_IMBALANCE_SCORE	0.0184		2.1127e-09,4.2681e-09																						0.0					
chr10:43613843	G/T	G	SNV		RET	exonic	1								59.94	p.(=)		1081	G=0.4006, T=0.5994		Present				+	13	NM_020975.4	c.2307G>T	synonymous	1.34				Cadherin domain,Protein kinase domain,Protein tyrosine kinase	rs1800861		0.277 (ref)	0.2347	0.1246	0.1974	YES	ATP binding,MAPKKK cascade,calcium ion binding,cellular response to retinoic acid,embryonic epithelial tube formation,endosome membrane,enteric nervous system development,homophilic cell adhesion,induction of apoptosis,integral to membrane,integral to plasma membrane,membrane,membrane protein proteolysis,nervous system development,neural crest cell migration,neuron maturation,nucleotide binding,positive regulation of cell adhesion mediated by integrin,positive regulation of cell migration,positive regulation of metanephric glomerulus development,positive regulation of neuron projection development,positive regulation of transcription, DNA-dependent,posterior midgut development,protein binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of cell adhesion,response to pain,signal transduction,transmembrane receptor protein tyrosine kinase activity,ureteric bud development	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo3,4-DPyrimidin-4-Ylamine,4-BROMO-2-FLUORO-N-(4E)-6-METHOXY-7-(1-METHYLPIPERIDIN-4-YL)METHOXYQUINAZOLIN-4(1H)-YLIDENEANILINE,Imatinib	untested	0.00001	5670.03	G=433, T=648		G=227/206, T=336/312	1	
